Aytu BioScience (AYTU) Announces Publication of Significant MiOXSYS Data
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Aytu BioScience, Inc. (OTC: AYTU) announced that clinical data demonstrating the reproducibility and reliability of its novel infertility diagnosis platform MiOXSYS has been published in the peer-reviewed, scientific journal Reproductive BioMedicine Online. The data establish a clear protocol for reproducible sampling and a clinical cut-off value for distinguishing infertile men from healthy ones.
In the article titled, "Diagnostic application of oxidation-reduction potential assay for measurement of oxidative stress: clinical utility in male factor infertility," researchers used MiOXSYS to compare the semen of control volunteers versus infertile patients for signs of oxidative stress (OS) by measuring sORP (static oxidation-reduction potential), which directly measures the balance of harmful reactive oxygen species versus antioxidants. They found a significant difference in sORP between control volunteers (1.59 ± 0.29 mV/106 sperm/ml) versus infertile volunteers (6.22 ± 1.10 mV/106 sperm/ml) (P = 0.004). This difference was even more significant in the subset of infertile individuals presenting with varicocele (P = 0.0003).
The variability of the MiOXSYS readings was also analyzed to assess reproducibility across multiple users. The coefficients of variation for three independent users of the MiOXSYS platform were 7.98%, 5.72%, and 11.96%, with an average difference between any two replicates of < 0.1 mV/106 sperm/ml. Variability analysis between users yielded a coefficient of variation of 3.61%, with no statistically significant difference between the three users' readings. This reproducibility confirms the suitability of MiOXSYS for broad use in the clinical setting.
The optimal cut-off value to diagnose oxidative stress damage of sperm cells was calculated using a ROC curve analysis. An sORP value of 1.36 mV/106 sperm/ml resulted in a test accuracy rate of 75%, specificity of 83%, and positive predictive value of 85%. There was a strong, statistically significant, inverse correlation between sORP and all major parameters of male factor infertility, specifically sperm concentration, total sperm count, motility, and morphology. The significance of this inverse correlation is that as the sORP reading increased, all fertility parameters declined proportionally, again confirming the clinical validity of diagnosing male infertility using MiOXSYS.
Lead author and Director of Research at the American Center for Reproductive Medicine at the Cleveland Clinic, Ashok Agarwal, Ph.D., wrote, "This ORP test is able to assess OS directly in semen samples, thus potentially making it a better indicator of OS in male infertility than currently used single markers such as reactive oxygen species, total antioxidant capacity, or malondialdehyde. This test also overcomes many of the limitations of these other assays, which are tedious and time consuming, require special technical skills, and need large sample volumes."
Dr. Agarwal continued, "Given the high sensitivity and predictive value of our preferred seminal sORP cut-off of 1.36 mV/106 sperm/ml, we believe that ORP testing will be clinically useful in identifying OS in men at risk for infertility that would otherwise go undetected with a routine semen analysis."
Josh Disbrow, Chief Executive Officer of Aytu BioScience, Inc., stated, "This study adds to the growing body of clinical evidence supporting the potential of MiOXSYS to diagnose male factor infertility due to oxidative stress. This validates our belief that the quick and easy MiOXSYS system has the potential to fill a clinical gap in the assessment of semen health. Equipping fertility clinics and andrology laboratories with this additional tool to aid in their diagnosis of male infertility will enable clinicians to employ the proper strategies to improve a patient's semen quality and overall fertility. The MiOXSYS system is already CE Marked and commercialized abroad, and Aytu is actively working to move MiOXSYS through the U.S. FDA approval process and into the U.S. market."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Voyager Therapeutics (VYGR) Offers Update on Phase 1b Trial of VY-AADC01 for Advanced Parkinson's Disease
- Minerva Neurosciences (NERV) Reports Additional Data Analyses From Phase IIb Trial of MIN-101 in Schizophrenia
- Rexahn Pharma (RNN) Presents Update of Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Pancreatic Cancer at ASCO
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!